PEARL THERAPEUTICS APPOINTS CHARLES (CHUCK) BRAMLAGE PRESIDENT AND CHIEF EXECUTIVE OFFICER
Redwood City, CA – February 24, 2011 – Pearl Therapeutics announced today the appointment of Chuck Bramlage to the position of president and chief executive officer. In addition, Mr. Bramlage will join the Company’s Board of Directors. Both appointments were effective as of February 22, 2011. “Chuck brings almost 30 years of pharmaceutical and biotechnology leadership experience to Pearl,” said James W. Young, PhD, chairman of the Pearl Board of Directors and venture partner at 5AM Ventures. “His expertise in the respiratory space, familiarity with both biotechnology and pharmaceutical operations, and understanding of the global commercial landscape will be of critical importance as we advance development of our lead COPD program through a rigorous phase 2b clinical program and toward the market.”
Mr. Bramlage previously held several executive positions at Covidien plc, most recently president of pharmaceutical products. Earlier, he served as president of European operations at Valeant Pharmaceuticals International and president and chief executive officer of BattellePharma, Inc., a specialty pharmaceutical company developing inhaled products. In addition, he was formerly the vice president of respiratory global commercial development and vice president of U.S. respiratory and cardiovascular marketing for GlaxoSmithKline, where he led the team responsible for the global launch of Seretide®/Advair® and the U.S. launch of Flovent®. Dr. Young continued, “On behalf of the Board of Directors and management team at Pearl, I would like to thank Howard Rosen, who graciously took the helm as interim president and chief executive officer of Pearl while we conducted this search. We look forward to Howie’s continued counsel as he returns to his former role as a member of the Pearl Board of Directors.”
About Pearl Therapeutics
Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma Leveraging its proprietary particle technology, as well as formulation and product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals therapies that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.